Empagliflozin decreases remnant‐like particle cholesterol in type 2 diabetes patients with insulin resistance
Open Access
- 27 December 2017
- journal article
- research article
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 9 (4) , 870-874
Abstract
Aims/Introduction: Remnant lipoproteins are thought to be atherogenic. Remnant‐like particle cholesterol (RLP‐C), which reflects the levels of various kinds of remnant lipoproteins in the blood, has a significant correlation with insulin resistance.Materials and Methods: In the present study, we measured the effect of empagliflozin (EMPA) on the levels of RLP‐C, and investigated whether EMPA‐mediated change in RLP‐C is associated with a change in insulin resistance in type 2 diabetes patients who have insulin resistance.Results: Patients were allocated to receive a placebo (n = 51) or EMPA (n = 58) as an add‐on treatment. Fasting blood samples were collected before and 12 weeks after this intervention. EMPA significantly decreased glycated hemoglobin, bodyweight, systolic blood pressure, plasma triglycerides, liver transaminases and estimated glomerular filtration rate, and increased high‐density lipoprotein cholesterol. Furthermore, EMPA decreased RLP‐C and homeostatic model assessment of insulin resistance. In the placebo group, there were no significant changes in these factors except for slight increases in liver transaminases. Multiple regression analysis showed that the change in homeostatic model assessment of insulin resistance (P = 0.0102) and the change in alanine aminotransferase (P = 0.0301) were significantly associated with the change in RLP‐C in the EMPA group. The change in RLP‐C significantly correlated with the change in homeostatic model assessment of insulin resistance (Pearson correlation coefficient 0.503, 95% confidence interval 0.199–0.719; P = 0.00241).Conclusion: EMPA decreases RLP‐C levels, which is closely associated with amelioration of insulin sensitivity in diabetes patients who have insulin resistance.Keywords
This publication has 17 references indexed in Scilit:
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine, 2015
- SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trialsDiabetes & Vascular Disease Research, 2015
- Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes MellitusDrugs, 2014
- Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patientsJournal of Clinical Investigation, 2014
- Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose productionJournal of Clinical Investigation, 2014
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplantation, 2012
- Relationships between cholesterol homoeostasis and triacylglycerol-rich lipoprotein remnant metabolism in the metabolic syndromeClinical Science, 2003
- Relationship between insulin-resistance and remnant-like particle cholesterolAtherosclerosis, 2002
- Relation between RLP-triglyceride to RLP-cholesterol ratio and particle size distribution in RLP-cholesterol profiles by HPLCClinica Chimica Acta, 2000
- Remnant Lipoprotein Levels in Fasting Serum Predict Coronary Events in Patients With Coronary Artery DiseaseCirculation, 1999